| Trial ID: | L0849 |
| Source ID: | NCT02721888
|
| Associated Drug: |
Liraglutide
|
| Title: |
Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes
|
| Acronym: |
LIRA-NAFLD/LIP
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
Drug: Liraglutide;Drug: MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy);Biological: Blood sample;Other: Kinetic substudy (10 patients)
|
| Outcome Measures: |
Effect of liraglutide on fatty liver content evaluated by proton-spectroscopy (1H-spectroscopy and lipoprotein kinetics, in patients with type 2 diabetes;Effects of liraglutide on Very Low Density Lipoprotein 1 (VLDL1) apolipoprotein B (apoB) production rate;Effects of liraglutide on Very Low Density Lipoprotein 2 (VLDL2) apolipoprotein B (apoB) production rate;Effects of liraglutide on Intermediate Density Lipoprotein (IDL) apolipoprotein B (apoB) production rate;Effects of liraglutide on Low Density Lipoprotein (LDL) apolipoprotein B (apoB) production rate;Effects of liraglutide on High Density Lipoprotein (HDL) apolipoprotein A1 (apoA1) production rate;Effects of liraglutide on Very Low Density Lipoprotein 1 (VLDL1) apolipoprotein B (apoB) fractional catabolic rate;Effects of liraglutide on Very Low Density Lipoprotein 2 (VLDL2) apolipoprotein B (apoB) fractional catabolic rate;Effects of liraglutide on Intermediate Density Lipoprotein (IDL) apolipoprotein B (apoB) fractional catabolic rate;Effects of liraglutide on Low Density Lipoprotein (LDL) apolipoprotein B (apoB) fractional catabolic rate;Effects of liraglutide on High Density Lipoprotein (HDL) apolipoprotein A1 (apoA1) fractional catabolic rateModification of body weight;Modification of subcutaneous fat by Magnetic Resonance Imaging (MRI);Modification of visceral fat by Magnetic Resonance Imaging (MRI)
|
| Sponsor/Collaborators: |
Centre Hospitalier Universitaire Dijon
|
| Gender: |
All
|
| Age: |
18 Yearsnan
|
| Phases: |
Phase 4
|
| Enrollment: |
120
|
| Study Type: |
Interventional
|
| Study Designs: |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
|
| Start Date: |
29/02/2016
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
11 April 2016
|
| Locations: |
France
|
| URL: |
https://clinicaltrials.gov/show/NCT02721888
|
